ClinVar Miner

Submissions for variant NM_005732.4(RAD50):c.1794-1G>A

gnomAD frequency: 0.00001  dbSNP: rs587781742
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000566085 SCV000663701 likely pathogenic Hereditary cancer-predisposing syndrome 2020-05-26 criteria provided, single submitter clinical testing The c.1794-1G>A intronic variant results from a G to A substitution one nucleotide upstream from coding exon 12 of the RAD50 gene. This nucleotide position is highly conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to abolish the native splice acceptor site; however, direct experimental evidence is unavailable. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp RCV000566085 SCV001231869 pathogenic Hereditary cancer-predisposing syndrome 2024-09-05 criteria provided, single submitter clinical testing This sequence change affects an acceptor splice site in intron 11 of the RAD50 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or altered protein product. This variant is present in population databases (rs587781742, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with RAD50-related conditions. ClinVar contains an entry for this variant (Variation ID: 480451). Studies have shown that disruption of this splice site results in activation of a cryptic splice site, and produces a non-functional protein and/or introduces a premature termination codon (internal data). For these reasons, this variant has been classified as Pathogenic.
Sema4, Sema4 RCV002257845 SCV002538460 likely pathogenic Nijmegen breakage syndrome-like disorder 2021-05-18 criteria provided, single submitter curation
Baylor Genetics RCV002257845 SCV004207444 likely pathogenic Nijmegen breakage syndrome-like disorder 2022-04-07 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.